Successful Reduction of SARS-CoV-2 Viral Load by Photodynamic Therapy (PDT) Verified by QPCR – A Novel Approach in Treating Patients in Early Infection Stages

{"title":"Successful Reduction of SARS-CoV-2 Viral Load by Photodynamic Therapy (PDT) Verified by QPCR – A Novel Approach in Treating Patients in Early Infection Stages","authors":"","doi":"10.33140/mcr.05.11.04","DOIUrl":null,"url":null,"abstract":"Background: The Covid-19 pandemic is affecting Global Health and the world‘s economy dramatically since early 2020. After a temporary slowdown in summer 2020 the infection numbers and death rates have been increasing again in recent months leading to various restrictions of social and economic life in many countries. Latest developments of new vaccinations seem to be promising; however large-scale production and worldwide distribution logistics take time while questions such as length of immune protection, long-term side-effects etc. are remaining unclear at this point. Furthermore, vaccination is a preventive approach and not a therapy for acutely infected patients. Thus, there are still therapies needed to help people with Covid-19 Infections. The objective of this study was to evaluate if Photodynamic Therapy (PDT) with Riboflavin and a specially designed light treatment kit would be able to fill this gap and to help people in early stages of infection. This may lead to a relief of the hospitals and intensive care stations. Methods: This study was made up of two groups with 20 patients each with the experiment (verum) group receiving Photodynamic Therapy and daily testing and a control group receiving conventional care plus testing. All patients in both groups had positive Covid-19 test results at the beginning of the study being in an early infection stage with mild symptoms like fever, dry cough, headache, hard breathing, fatigue etc. QPCR tests with CT-viral load were performed on day 1, 2, 3, 4, 5 and 7 in the experiment group and on day 1, 3, 5 and 7 in the control group. Results: All 20 patients in the experiment group showed significant improvement in clinical symptoms and viral load assessment within the 5 days of PDT treatment. 14 out of 20 patients had a negative QPCR test after 5 days of treatment with PDT while the other 6 patients also showed significantly reduced viral load. 20 patients in the control group with conventional care were tested 3 times within 5 days and no significant improvement could be seen clinically or in viral load assessment. Conclusion: In this primary study the potential of Photodynamic Therapy (PDT) against SARS-CoV-2 could be shown in early infections stages. PDT proved to be successful in improving clinical symptoms, lowering viral loads and in preventing hospitalisation and intensive care treatments. This treatment is easy to perform, cost effective and can be done at home. It can be used for prevention after contact with infected people or in case of positive testing but also in early cases with mild to moderate clinical symptoms.","PeriodicalId":9304,"journal":{"name":"British Medical Journal (Clinical research ed.)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Medical Journal (Clinical research ed.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33140/mcr.05.11.04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11

Abstract

Background: The Covid-19 pandemic is affecting Global Health and the world‘s economy dramatically since early 2020. After a temporary slowdown in summer 2020 the infection numbers and death rates have been increasing again in recent months leading to various restrictions of social and economic life in many countries. Latest developments of new vaccinations seem to be promising; however large-scale production and worldwide distribution logistics take time while questions such as length of immune protection, long-term side-effects etc. are remaining unclear at this point. Furthermore, vaccination is a preventive approach and not a therapy for acutely infected patients. Thus, there are still therapies needed to help people with Covid-19 Infections. The objective of this study was to evaluate if Photodynamic Therapy (PDT) with Riboflavin and a specially designed light treatment kit would be able to fill this gap and to help people in early stages of infection. This may lead to a relief of the hospitals and intensive care stations. Methods: This study was made up of two groups with 20 patients each with the experiment (verum) group receiving Photodynamic Therapy and daily testing and a control group receiving conventional care plus testing. All patients in both groups had positive Covid-19 test results at the beginning of the study being in an early infection stage with mild symptoms like fever, dry cough, headache, hard breathing, fatigue etc. QPCR tests with CT-viral load were performed on day 1, 2, 3, 4, 5 and 7 in the experiment group and on day 1, 3, 5 and 7 in the control group. Results: All 20 patients in the experiment group showed significant improvement in clinical symptoms and viral load assessment within the 5 days of PDT treatment. 14 out of 20 patients had a negative QPCR test after 5 days of treatment with PDT while the other 6 patients also showed significantly reduced viral load. 20 patients in the control group with conventional care were tested 3 times within 5 days and no significant improvement could be seen clinically or in viral load assessment. Conclusion: In this primary study the potential of Photodynamic Therapy (PDT) against SARS-CoV-2 could be shown in early infections stages. PDT proved to be successful in improving clinical symptoms, lowering viral loads and in preventing hospitalisation and intensive care treatments. This treatment is easy to perform, cost effective and can be done at home. It can be used for prevention after contact with infected people or in case of positive testing but also in early cases with mild to moderate clinical symptoms.
QPCR验证光动力疗法(PDT)成功降低SARS-CoV-2病毒载量——治疗早期感染患者的新方法
背景:自2020年初以来,新冠肺炎大流行对全球卫生和世界经济产生了巨大影响。在2020年夏季短暂放缓之后,近几个月来感染人数和死亡率再次上升,导致许多国家的社会和经济生活受到各种限制。新疫苗的最新发展似乎很有希望;然而,大规模生产和全球配送物流需要时间,而免疫保护时间长短、长期副作用等问题目前仍不清楚。此外,疫苗接种是一种预防方法,而不是急性感染患者的治疗方法。因此,仍然需要治疗方法来帮助Covid-19感染者。本研究的目的是评估核黄素光动力疗法(PDT)和专门设计的光治疗试剂盒是否能够填补这一空白,并帮助处于感染早期阶段的人们。这可能会减轻医院和重症监护站的负担。方法:本研究将患者分为两组,每组20例,实验组接受光动力治疗和日常检测,对照组接受常规护理加检测。两组患者在研究开始时都有阳性的Covid-19检测结果,处于早期感染阶段,症状轻微,如发烧、干咳、头痛、呼吸困难、疲劳等。实验组于第1、2、3、4、5、7天,对照组于第1、3、5、7天进行ct病毒载量QPCR检测。结果:试验组20例患者在PDT治疗5 d内临床症状及病毒载量评估均有明显改善。20例患者中有14例在PDT治疗5天后QPCR检测为阴性,另外6例患者的病毒载量也显著降低。常规治疗组20例患者5天内检测3次,临床及病毒载量评估均未见明显改善。结论:在这项初步研究中,光动力疗法(PDT)对抗SARS-CoV-2的潜力可以在早期感染阶段显示出来。事实证明,PDT在改善临床症状、降低病毒载量和预防住院和重症监护治疗方面取得了成功。这种治疗方法操作简单,成本效益高,可以在家完成。它既可用于与感染者接触后的预防,也可用于检测呈阳性的病例,但也可用于有轻度至中度临床症状的早期病例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信